Snellen

EyeDNA Therapeutics Announces Positive 24-month Data Presented at ARVO from Ongoing Phase I/II Trial of HORA-PDE6b Gene Therapy in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b

Retrieved on: 
Tuesday, May 7, 2024
Optical coherence tomography, Șaeș, Patient, Retinitis pigmentosa, Safety, Research, PDE6B, Paratriathlon, Chorioretinitis, Visual impairment, Natural history, Disease, OCT, Snellen, Eye, GVF, ARVO, Visual acuity, Ageing, Pharmaceutical industry

These data were reported during an oral presentation* on May 6, at the Association for Research in Vision and Ophthalmology (ARVO) 2024 meeting in Seattle, WA, US.

Key Points: 
  • These data were reported during an oral presentation* on May 6, at the Association for Research in Vision and Ophthalmology (ARVO) 2024 meeting in Seattle, WA, US.
  • The positive 24-month follow-up data presented confirm results from the previous interim analysis of the trial conducted at the 12-month follow-up point and support preparation for a registrational trial for HORA-PDE6b in PDE6b RP patients.
  • Further discussions with health authorities in the US and Europe are planned to define the optimal path to making HORA-PDE6b available to PDE6b RP patients.
  • The treatment was administered in the more affected eye while the other eye served as an untreated control.

Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome

Retrieved on: 
Wednesday, April 10, 2024
Health, Diabetes, Neurology, Genetics, Clinical Trials, Pharmaceutical, FDA, DSM-IV codes, Glycated hemoglobin, Cell, Safety, PB, Blood, Apoptosis, Paratriathlon, C-peptide, Endoplasmic reticulum, Doctor of Philosophy, WFS1, Disease, AMX0035, Week, Wolfram syndrome, Science, Snellen, Patient, Diarrhea, Amylyx Pharmaceuticals, Data analysis, PGIC, Samuel, Metabolism, Aes, Visual acuity, Clinical trial, AUC, Medication, Division, Pharmaceutical industry

“I have been studying Wolfram syndrome and caring for people with the disease for more than 20 years.

Key Points: 
  • “I have been studying Wolfram syndrome and caring for people with the disease for more than 20 years.
  • Outcomes for people with Wolfram syndrome consistently worsen over time, so disease stabilization alone is clinically meaningful for both patients and their doctors.
  • Because of the clear link between WFS1 mutations and ER stress, Wolfram syndrome is considered a prototypical ER stress disorder.
  • Amylyx announced that the FDA granted orphan drug designation to AMX0035 for the treatment of Wolfram syndrome in November 2020.

LensCrafters Launches Second Season of Its Immersive Experience on Roblox

Retrieved on: 
Thursday, April 11, 2024
Odyssey, LensCrafters, Map, Lang, Season, Communication, Season 2, American Optometric Association, Dust, Lens, EssilorLuxottica, Chart, Snellen, Ishihara test

NEW YORK, April 11, 2024 /PRNewswire/ -- LensCrafters, part of EssilorLuxottica and one of the largest optical retail brands in North America, announced today the launch of LensCrafters Eye Odyssey: World of Optics, the second season of the Eye Odyssey series on Roblox, a global immersive platform for communication and connection. With more than 300,000 users to date since debuting in October 2023, Season 2 will engage users throughout different game dynamics, each of them supported by a strong educational message to promote healthy eye care habits.

Key Points: 
  • NEW YORK, April 11, 2024 /PRNewswire/ -- LensCrafters , part of EssilorLuxottica and one of the largest optical retail brands in North America, announced today the launch of LensCrafters Eye Odyssey: World of Optics , the second season of the Eye Odyssey series on Roblox, a global immersive platform for communication and connection.
  • "We're thrilled to see the evolution of LensCrafters Eye Odyssey with the launch of Season 2 on Roblox," said Alfonso Cerullo, President of LensCrafters.
  • "With the success of the first season where we engaged with users on Roblox to drive awareness regarding maintaining healthy vision, we were able to connect with a new community through a fun interactive experience.
  • The second chapter of the series gives the brand the opportunity to further educate this audience about vision health and its impact on overall well-being."

Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema

Retrieved on: 
Thursday, December 15, 2022
Eye, CST, Patient, Inflammation, Disulfiram-like drug, PKI, MAD, Severe cognitive impairment, Safety, Diabetic retinopathy, Retina, Pharmacokinetics, DR, DME, World Diabetes Day, Diabetes, SAD, Visual acuity, Risk, Bradykinin, Kallikrein, Pathophysiology, HIV disease progression rates, Injection, Congenital hyperinsulinism, Pharmaceutical industry, Rezolution Pictures, Snellen

The invasive route of administration, coupled with inadequate responsiveness in some patients, leads to overall undertreatment and suboptimal vision outcomes in DME patients.

Key Points: 
  • The invasive route of administration, coupled with inadequate responsiveness in some patients, leads to overall undertreatment and suboptimal vision outcomes in DME patients.
  • Patients who have previously received more than three anti-VEGF injections prior to the study will be excluded.
  • The study is expected to enroll approximately 100 patients overall, across approximately 25 investigational sites in the United States.
  • Rezolute is also developing RZ402, an orally available plasma kallikrein inhibitor, for the treatment of diabetic macular edema.

M&S Technologies', Clinical Trial Suite (CTS) offers randomized testing with a full array of symbol sets

Retrieved on: 
Friday, June 10, 2022
Reading Center, New York, US, CTS, LogMAR chart, CSV, Bias, Snellen, Algorithm, CE, PMA, XML, M&S, EDC, University, Medical device, Medical imaging

NILES, Ill., June 10, 2022 /PRNewswire-PRWeb/ -- M&S Technologies', Clinical Trial Suite (CTS) offers randomized testing with a full array of symbol sets.

Key Points: 
  • Immediately, export test results to any EDC or Reading Center without the need and expense of Secondary Reviewers.
  • For those conducting the most innovative research, CTS testing algorithms consistently ensure the most accurate ophthalmic clinical trial outcomes.
  • For more information on the Clinical Trial Suite (CTS) modules, please call 1-847-763-0500.
  • M&S is dedicated to bringing high quality, extremely accurate testing products to eye-care professionals, optometry schools, and universities.

Alcon Strengthens Leadership in IOL Innovation with Launch of Clareon Portfolio in the U.S.

Retrieved on: 
Monday, March 7, 2022
Health, Medical Devices, Surgery, Other Health, General Health, Pharmaceutical, Optical, Aphakia, Population, S, DOI, Direction, Use, Radiation, Comparison, Physician, Ageing, PMID, Mark (given name), Family, Adult, Cataract, Quality of life, Astigmatism, Glasses, National Institute for Health and Care Excellence, Ophthalmology, Incidence, Trial of the century, Steroid, Eye, Approximation error, Flaxman, NYSE, CA, Haze, Safety, Snellen, Patient, Severe cognitive impairment, Innovation, Systematic review, Rotation, Katherine Clerk Maxwell, Intraocular lens, Retina, Refraction, Presbyopia, GLARE, Meta-analysis, Diabetes, Glaucoma, Telescopic sight, Medical device, Veterinary medicine, Medicine, Personal protective equipment, Fused quartz, Alcon, MD, IOL

At Alcon, we are consistently pushing the boundaries to deliver transformational innovation to cataract surgeons and their patients, said Ian Bell, President, Global Business & Innovation, Alcon.

Key Points: 
  • At Alcon, we are consistently pushing the boundaries to deliver transformational innovation to cataract surgeons and their patients, said Ian Bell, President, Global Business & Innovation, Alcon.
  • Alcon will be rolling out the Clareon family of IOLs in international markets throughout 2022 and 2023.
  • More than 92% of cataract surgeries are considered successful, and patients typically can return to their normal routines within 24 hours.21
    The family of Clareon intraocular lenses (IOLs) includes the Clareon Aspheric Hydrophobic Acrylic and Clareon Aspheric Toric IOLs, the Clareon PanOptix Trifocal Hydrophobic IOL, Clareon PanOptix Toric, Clareon Vivity Extended Vision Hydrophobic Posterior Chamber IOL and Clareon Vivity Toric IOLs.
  • In addition, the Clareon Toric IOLs are indicated to correct pre-existing corneal astigmatism at the time of cataract surgery.

M&S Technologies introduces the CTS Distance One™ ultrasonic distance measurement device for use in ophthalmic Clinical Trials

Retrieved on: 
Thursday, January 6, 2022
Snellen, XML, CTS, CSV, ISO, ANSI, LogMAR chart, Science, Reading Center, New York, US, University, M&S, Algorithm, PMA, EDC, Ultrasound, Medical imaging

NILES, Ill., Jan. 6, 2022 /PRNewswire-PRWeb/ --Distance One is an ultrasonic measurement device that maintains a specified calibrated display-to-subject separation for precise distance testing.

Key Points: 
  • NILES, Ill., Jan. 6, 2022 /PRNewswire-PRWeb/ --Distance One is an ultrasonic measurement device that maintains a specified calibrated display-to-subject separation for precise distance testing.
  • "Ultrasonic sensors in the Distance One send, receive, and verify data every 0.025 seconds.
  • "Further, the Distance One device is accurate to within 1 cm and seamlessly integrates with all CTS systems for both near and intermediate testing."
  • CTS has been used in over 140 clinical trials and is recognized by the US FDA as an acceptable method of vision testing in all phases of clinical trials including PMA trials.